(NASDAQ: AGIO) Agios Pharmaceuticals's forecast annual revenue growth rate of 54.91% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.6%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.65%.
Agios Pharmaceuticals's revenue in 2026 is $140,843,000.On average, 12 Wall Street analysts forecast AGIO's revenue for 2026 to be $11,281,296,372, with the lowest AGIO revenue forecast at $10,140,128,231, and the highest AGIO revenue forecast at $11,980,471,192. On average, 12 Wall Street analysts forecast AGIO's revenue for 2027 to be $21,072,734,337, with the lowest AGIO revenue forecast at $12,908,118,879, and the highest AGIO revenue forecast at $26,887,428,607.
In 2028, AGIO is forecast to generate $31,422,196,346 in revenue, with the lowest revenue forecast at $23,776,728,659 and the highest revenue forecast at $39,422,933,360.